Lack of an association between matrix metalloproteinase polymorphisms and coronary heart disease in a Han Chinese population

被引:1
作者
Wang, C. M. [1 ]
Ye, H. D. [2 ]
Li, Y. R. [2 ]
Hong, Q. X. [2 ]
Tang, L. L. [2 ]
Zhou, A. N. [2 ]
Xu, M. Q. [3 ]
Duan, S. W. [2 ]
机构
[1] Peoples Hosp Yinzhou, Dept Cardiol, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Ningbo 315211, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, BioX Inst, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
Coronary heart disease; Matrix metalloproteinase; Polymorphism; Han Chinese population; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; RISK; GENE; ATHEROSCLEROSIS; MATRIX-METALLOPROTEINASE-9; SUSCEPTIBILITY; VARIANTS;
D O I
10.4238/2015.October.9.14
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coronary heart disease (CHD) has become a leading cause of human deaths worldwide. Recent studied showed that polymorphisms of the matrix metalloproteinase (MMP) genes played important roles in extracellular matrix remodeling and contribute to the pathogenesis of vascular diseases. Here, we investigated whether these MMP gene polymorphisms were associated with CHD in Han Chinese. Our case-control study was involved with 1509 unrelated individuals, including 777 CHD cases and 732 controls. We selected a total of five polymorphisms whose genotypes were determined using Sequenom iPLEX technology. Our results showed there were no significant associations between the five MMP gene polymorphisms and CHD risk at either genotype or allele levels (P > 0.05). Further subgroup analyses by sex were also unable to reveal any significant association (P > 0.05). In conclusion, no significant associations were found between the five MMP gene polymorphisms and the risk of CHD in Han Chinese.
引用
收藏
页码:12254 / 12261
页数:8
相关论文
共 39 条
[1]   The Role of Matrix Metalloproteinase-2 Promoter Polymorphisms in Coronary Artery Disease and Myocardial Infarction [J].
Alp, Ebru ;
Menevse, Sevda ;
Tulmac, Murat ;
Yilmaz, Akin ;
Yalcin, Ridvan ;
Cengel, Atiye .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (04) :193-202
[2]  
[Anonymous], 1979, Circulation, V59, P607
[3]   HUMAN MACROPHAGE METALLOELASTASE - GENOMIC ORGANIZATION, CHROMOSOMAL LOCATION, GENE LINKAGE, AND TISSUE-SPECIFIC EXPRESSION [J].
BELAAOUAJ, A ;
SHIPLEY, JM ;
KOBAYASHI, DK ;
ZIMONJIC, DB ;
POPESCU, N ;
SILVERMAN, GA ;
SHAPIRO, SD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14568-14575
[4]   Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease [J].
Bench, Travis J. ;
Jeremias, Allen ;
Brown, David L. .
PHARMACOLOGICAL RESEARCH, 2011, 64 (06) :561-566
[5]  
Benjamin Mina M, 2012, Exp Suppl, V103, P209, DOI 10.1007/978-3-0348-0364-9_7
[6]   Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J].
Blankenberg, S ;
Rupprecht, HJ ;
Poirier, O ;
Bickel, C ;
Smieja, M ;
Hafner, G ;
Meyer, J ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 107 (12) :1579-1585
[7]   Matrix metalloproteinase inhibition after myocardial infarction - A new approach to prevent heart failure? [J].
Creemers, EEJM ;
Cleutjens, JPM ;
Smits, JFM ;
Daemen, MJAP .
CIRCULATION RESEARCH, 2001, 89 (03) :201-210
[8]   POWER AND SAMPLE-SIZE CALCULATIONS - A REVIEW AND COMPUTER-PROGRAM [J].
DUPONT, WD ;
PLUMMER, WD .
CONTROLLED CLINICAL TRIALS, 1990, 11 (02) :116-128
[9]   Lp-PLA2- a novel risk factor for high-risk coronary and carotid artery disease [J].
Epps, K. C. ;
Wilensky, R. L. .
JOURNAL OF INTERNAL MEDICINE, 2011, 269 (01) :94-106
[10]   Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows [J].
Excoffier, Laurent ;
Lischer, Heidi E. L. .
MOLECULAR ECOLOGY RESOURCES, 2010, 10 (03) :564-567